Modalis Gains Japanese Patent for DM1 Gene Therapy

Modalis Therapeutics Corporation (JP:4883) has released an update.

Modalis Therapeutics Corporation has been granted a Japanese patent for MDL-202, their CRISPR-GNDM® based gene therapy drug designed to treat Myotonic Dystrophy Type 1 (DM1). The treatment targets the DMPK gene, aiming to effectively silence its abnormal expression in muscle tissue using a muscle-specific promoter within an adeno-associated virus vector. This patent solidifies Modalis’s IP rights in Japan, following a previous patent issue in China, and anticipates further international patent grants.

For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.